Akèy › Kansè Poumon ki pa ti selil › Nebraska › Lincoln
Etid klinik pou Kansè Poumon ki pa ti selil nan Lincoln, NE
16 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Lincoln (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Nebraska Hematology-Oncology /ID# 272970, Lincoln
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 2/3
- Nho - Revive Research Institute /ID# 277569, Lincoln
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Cancer Partners of Nebraska, Lincoln
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Ap rekriteFaz 3
- Nebraska Hematology-Oncology - Revive Research Institute LLC, Lincoln
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- NHO Revive Research Institute, LLC ( Site 3218), Lincoln
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Ap rekriteFaz 3
- NHO Revive Research Institute LLC ( Site 0118), Lincoln
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Lincoln
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- NHO Revive Research Institute, LLC, Lincoln
- NHO Support Center, Lincoln
- Cancer Partners of Nebraska, Lincoln
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Ap rekriteFaz 3
- Cancer Partners of Nebraska, Lincoln
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Ap rekriteFaz 2
- Cancer Partners of Nebraska, Lincoln
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Cancer Partners of Nebraska, Lincoln
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Lincoln
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- NHO Revive Research Institute, Lincoln
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Lincoln
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Nebraska Hematology-Oncology, Lincoln
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA14-0, Lincoln
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Lincoln
- Ensifizyans kadyak8 etid
- Kansè poumon7 etid
- Maladi atè koronè5 etid
- Skizofreni4 etid
- Kansè nan tete4 etid
- Kansè kolorektal4 etid
- Obèsite4 etid
- Skleroz Amiotrofik Lateral3 etid
- Kansè (tout kalite)3 etid
- Myelom Miltip3 etid
- Melanom3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.